Alnylam Pharmaceuticals Inc
XMUN:DUL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Alnylam Pharmaceuticals Inc
XMUN:DUL
|
US |
|
B
|
Bertrandt AG
SWB:BDT
|
DE |
|
M
|
Metacon AB (publ)
F:M16
|
SE |
|
C
|
Children's Place Inc
SWB:CP5
|
US |
|
A
|
Akwel SA
F:MW4
|
FR |
|
O
|
Otto Energy Ltd
OTC:OTTEF
|
AU |
Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals develops medicines based on RNA interference, or RNAi, a way to silence disease-causing genes. It does not make broad consumer products; it focuses on prescription drugs for serious genetic and rare diseases, along with some more common conditions where turning off a specific gene can help. Its main work is discovering, testing, and selling these therapies to physicians and patients through normal pharmaceutical channels. The company makes money by selling approved drugs and, in some cases, from collaboration deals tied to research, development, or product commercialization. Its customers are doctors, hospitals, specialty pharmacies, and health systems that prescribe its medicines, with insurers and government payers also playing a major role because these drugs are usually expensive specialty treatments. Alnylam’s role in the industry is to turn a new genetic science into targeted medicines that can address diseases where older drugs often treat symptoms rather than the root cause. What makes Alnylam different is its focus on RNAi as a drug platform. Instead of building a wide catalog of unrelated products, it concentrates on one core technology that can be applied to different diseases by silencing specific genes. That gives the company a clear niche in biopharma: it is both a drug developer and one of the main commercial proof points for RNAi medicines.
Alnylam Pharmaceuticals develops medicines based on RNA interference, or RNAi, a way to silence disease-causing genes. It does not make broad consumer products; it focuses on prescription drugs for serious genetic and rare diseases, along with some more common conditions where turning off a specific gene can help. Its main work is discovering, testing, and selling these therapies to physicians and patients through normal pharmaceutical channels.
The company makes money by selling approved drugs and, in some cases, from collaboration deals tied to research, development, or product commercialization. Its customers are doctors, hospitals, specialty pharmacies, and health systems that prescribe its medicines, with insurers and government payers also playing a major role because these drugs are usually expensive specialty treatments. Alnylam’s role in the industry is to turn a new genetic science into targeted medicines that can address diseases where older drugs often treat symptoms rather than the root cause.
What makes Alnylam different is its focus on RNAi as a drug platform. Instead of building a wide catalog of unrelated products, it concentrates on one core technology that can be applied to different diseases by silencing specific genes. That gives the company a clear niche in biopharma: it is both a drug developer and one of the main commercial proof points for RNAi medicines.
Record quarter: Alnylam posted more than $1.0 billion in combined net product revenue in Q1 2026, its first quarter ever above that threshold, up 121% year over year.
TTR momentum: AMVUTTRA drove the story, with global TTR revenue of $910 million, up 153% year over year, and management said the ATTR-CM launch remains on track.
Guidance held: The company reiterated its full-year 2026 guidance, including its TTR revenue target of $4.4 billion to $4.7 billion.
Pipeline progress: Alnylam highlighted positive vutrisiran data, fast enrollment in the nucresiran TRITON-CM study, and a 500-patient increase in that trial’s planned size.
Profitability: Q1 marked Alnylam’s third consecutive quarter of both GAAP and non-GAAP profitability, with $3.0 billion in cash, cash equivalents and marketable securities.
Commercial mix: Management said U.S. demand was the main driver of growth, while Germany pricing changes weighed on international revenue but were expected to become a net positive as CM launches expand overseas.
